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1 Introduction  
Decision-analytic models within HTA on the one hand require qualitative 
(structural) knowledge on the disease under consideration (e.g. spread of a 
disease and its influencing factors, which type of costs are incurred by the 
disease and where). On the other hand modellers need quantitative data to 
define the model parameters.  
Examples for the latter are data on the prevalence of a disease in a defined 
population at the starting point of the model, infection rates in cases of infec-
tious diseases or costs for treatment. The more precise these data are the 
more precise model results will be obtained, because uncertainty is mini-
mised.  
The aim of work package 4.2. is to define recommendations on how to pa-
rameterise models on the basis of secondary data including challenges and 
possible solutions.   
2 Research question 
The project group defined the following research questions:  
 
b What type of data are published in clinical studies on the diseases to 
be modelled in IFEDH (especially on infectious diseases) and on 
drugs/vaccination? 
b For which types of model parameters is it appropriate to do a (sys-
tematic) literature search?  
b What is the recommended strategy to search for literature on model 
parameterisation? Is the identification of literature different from 
standard search procedures for effectiveness of an intervention within 
an HTA?  
b Is it possible to obtain data from a clinical study in a less aggregated 
way as they are presented in publications (e.g. total number of pa-
tients with improved health status after drug treatment in contrast to 
presentation of this group disaggregated according to age or smoking 
status)? 
b What are the required characteristics for data obtained from pub-
lished literature? For example, should data be presented with their 
confidence intervals in contrast to point estimates only?   
b To what extent can a literature search be helpful to gain qualitative 
knowledge (for issues defined in work package 4.1)? What type of lit-
erature is useful (text books, literature on basic research etc.)? 
 
decision analytic models 
require qualitative and 
quantitative 
information 
e.g. prevalence data 
how to obtain 
quantitative 
information from 
secondary data? 
research questions 
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3 Aim 
The aim of this report is,  
b to provide an overview on methodological standards concerning the 
utilisation of different data sources for defining model parameters. 
The focus will be on data sources from secondary literature (pub-
lished clinical studies or meta-analyses). Other types of secondary 
data (e.g. routine data) will only be described briefly for reasons of 
completeness because they are addressed in another work package 
(WP 5).  
b to translate the generic standards concerning relevant data sources 
from manuals into the case study ‘Human papilloma virus vaccination 
modelling’ (HPV-vaccination modelling) including data on screening, 
vaccination, history of disease etc. This is to provide information for 
work package 8 (proof of concept). 
4 Method 
b HTA-manuals, country-specific guidelines on economic evaluation and 
published methodological standards on modelling are analysed. Rec-
ommendations on possible data sources, on the identification of data 
and on issues related to the correct handling of the data are extracted 
and summarised.   
b The information sources used for this part of the report is all the lit-
erature from work package 1.2 (where HTA-manuals have been iden-
tified by electronic and by hand search) as well as the overview on 
country-specific health economic evaluation guidelines on the ISPOR-
webpage (www.ispor.org).  
b We include documents in English or German language that are related 
to ‚western’ industrialised countries and that contain information on 
data sources for modelling that goes beyond a mere listing of data 
sources.  
b The recommendations are contrasted with the data identified in the 
‚HPV-vaccination literature’. This will be alongside the parameters 
that are required for modelling HPV-vaccination. Only parameters 
that are defined out of data in published literature are described. Pa-
rameters that are primarily based on further secondary data (routine 
data, official national statistics) are not included in the detailed de-
scription. 
 
Data that are found in the literature may not be in the format required for 
the model and may need to be adjusted. Several methods exist on how to ad-
just data by modelling. Information on these methods (e.g., methods for in-
corporating estimates of treatment effectiveness from clinical trials into a 
model) are addressed in a separate IFEDH report.  
 
aims:  
identifying standards on 
utilising data sources for 
model parameters 
application in case study 
HTA-manuals and 
guidelines are analysed 
information sources: 
earlier work and ISPOR 
webpage 
language: German and 
English 
contrasting standards 
with case study quoteHPV quotequotequote
modelling literaturequotequotequotequote 
standards on further 
data management are 
addressed in separate 
document 
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5 Potential data sources  
5.1 Identified literature 
Overall 43 references were available (figure 5.2-1). 13 documents were se-
lected for our purpose. One source out of these 13 documents [1] has been 
identified in the references of the primary documents and has been included 
because it specifically addresses the issue of data sources selection for mod-
elling, although it is not a manual or guideline in its strict sense.  
The remaining 30 documents were excluded because they did not contain 
enough information for answering our research questions (n=18), they came 
from ‘non-western’ countries (n=10) or they were written in a language 
other than German or English (n=2).  
5.2 Potential data sources for models 
In the documents a variety of data sources are mentioned that may be rele-
vant for defining model parameters. These will be classified and described in 
more detail in the following chapters including information on their poten-
tials and limitations. Table 5.2-1 summarises the information. 
Overall, neither document provides extensive information on the issue in 
question. Mostly, information is restricted to listing the different data 
sources including a brief description on their advantages and disadvantages.  
13 documents selected 
rest excluded 
data sources will be 
described in following 
chapters  
overall limited 
information available 
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Additional records identified 
through other sources  
parenn =  43 paren 
Records after duplicates removed 
parenn =  43 paren 
Full-text articles as-
sessed for eligibility 
parenn = 43  paren 
Full-text articles excluded, 
with reasons 
parenn =30 paren 
limited information n = 18 
inadequate health care 
system context n = 10 
language n = 2 
 Studies included in 
qualitative synthesis 
parenn = 13 paren 
 
 
Figure 5.2-1: PRISMA Flow Diagram for the selection of literature 
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5.2.1 Clinical studies and meta-analyses  
Randomised controlled trials parenRCTsparen and meta-analyses 
Experimental clinical studies (RCTs) and their meta-analyses are regarded 
as first choice data source for defining parameters related to the efficacy and 
effectiveness of a technology. However, their main limitation, which is the 
limited external validity and the restricted generalisability of results to the 
real world setting, is also recognised. Yet, in the absence of large scale ‘real 
world RCTs’ [2], classical RCTs are still the preferred source for effectiveness 
data compared to other data sources. 
In addition to efficacy/effectiveness information, RCTs may also be used to 
obtain information on costs, however two frequent problems in using clini-
cal studies for costing information are mentioned: Firstly, they may not 
cover all relevant cost-categories and secondly, the studies may not have 
been powered to detect cost differences [3]. Furthermore, in one manual it is 
pointed out that the simple currency conversion of values found in the litera-
ture is not accepted [4] which addresses the limitation of transferring inter-
national cost data to one’s own jurisdiction.  
Another guideline mentions that the control group of an experimental study 
may be used to obtain baseline probabilities on the natural history of disease 
[5]. 
While meta-analyses are explicitly and repeatedly mentioned as important 
data source for efficacy/effectiveness issues in those cases, where more than 
one study is available, the danger of using low quality meta-analyses (e.g. 
those that include studies selectively or those that include heterogeneous 
studies) is also pointed out [1, 6].   
In one reference, meta-analyses are presented as source for calculating tran-
sitional probabilities and as source for obtaining information on treatment 
failure [1]. However, the authors do not explain the method to be applied in 
detail. 
Further clinical studies 
Apart from RCTs and their potential to define the efficacy of an intervention, 
a number of further clinical studies are mentioned in the documents as a 
valid source for defining model parameters: data for parameters on test ac-
curacy of a diagnostic test may be obtained from test accuracy studies, data 
for defining prognostic parameters on morbidity or mortality may be ob-
tained from prognostic studies, data on incidences of future events can be 
found in risk-factor studies. Observational (clinical) studies may be a valid 
source for safety data, they provide ‘real-world’ data (for effectiveness) and 
data on compliance. The disadvantage that has been stated for the latter is 
that there is little control over confounding and certain types of bias. Fur-
thermore, observational studies may be of limited use if they lack a control 
group [6].  
Finally, one manual mentions that data on ‘health state values’ (values  for 
different health states in the model from 0 to 1 for the calculation of QALYs) 
may be derived from different clinical studies, however these should be 
treated with utmost caution and only be used if measured with the same in-
strument and in a similar patient population [4]. 
for 
efficacy/effectiveness: 
RCTs and meta-analysis, 
yet low external valdity 
RCTs also for limited 
cost information 
control groups of RCTs 
for baseline probabilities 
meta-analysis if more 
than one study 
available, yet bias 
possible 
further clinical studies 
especially for quotereal quotequotequote
worldquote safety data…quotequotequote  
…and possibly health 
state values 
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5.2.2 Epidemiological studies 
The terms ‘clinical studies’ and ‘epidemiological studies’ have not been ex-
plicitly defined in the manuals. Hence, it is unclear what the term ‘epidemi-
ological studies’ exactly refers to and if/how it is to be distinguished from 
clinical epidemiological studies. Nevertheless, the term ‘epidemiological 
studies’ has been mentioned in 3 manuals where they are regarded as a use-
ful source to extrapolate data from clinical trials and for identifying valid 
surrogate endpoints for patient relevant endpoints. Additionally, they may 
yield information on the current medical practice and they can be used for 
natural history data from which baseline probabilities can be obtained [5].  
However, they are limited by confounding and certain types of bias which is 
why they are not recommended for defining parameters on efficacy or effec-
tiveness. When epidemiological studies are used to define predictive func-
tions, the interpretation of these functions and the validity of transferring 
fixed risk functions onto the modelled study population need to be explained 
and justified.  
5.2.3 Routine data 
Eight out of the 13 selected documents explicitly mention several types of 
routine data. The terms that are used are ‘claims data’, ‘retrospective data 
sets’, ‘databases’, ‘Abrechnungsdaten’, ‘ Prozessdatenbanken’, ‘national data 
on healthcare resource groups (HRGs)’, ‚Routinedaten’, ‘validated databases’ 
or ‘administrative and accounting databases’. It is recommended that those 
data are assessed for relevance and completeness before they are used for 
modelling purposes.  
Authors mention as advantage that these sources contain data on large 
number of patients and may be appropriate if the relevant target population 
in the model is sufficiently depicted in the data (via diagnostic codes). They 
are also regarded as helpful for defining treatment paths or obtain informa-
tion on the behaviour of patients. Hence, they are a valuable source to obtain 
data on resource use or costs. However, they may as well be problematic in 
use if the definition of the model population includes parameters (e.g. clini-
cal results, specific patient characteristics) that are not coded in the data-
base.  
5.2.4 Registries 
Registries are mentioned in three manuals only [3, 7, 8], although the term 
‘observational studies’ that appears in other documents may also refer to 
registries. Authors point out that registries represent a real-life situation and 
may be helpful for defining predictive functions that describe the association 
between clinical event and resource use, quality of care, sick leave etc. Addi-
tionally, disease registries are mentioned in context with defining probabili-
ties of events. Yet, before using registries for defining model parameters, it is 
pointed out that the access need to be verified and the relevance of the regis-
try-data for the model parameters in question must be assessed. 
epidemiological studies 
for extrapolation, 
current practice and info 
on natural history of 
diseases 
limitation: confounding 
many manuals mention 
routine data 
advantage: large 
number of patients, 
data for resource 
use/costs 
disadvantage: model 
population may not be 
depicted in data 
registries represent real 
life situation: e.g. for 
predictive functions, 
probabilities 
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5.2.5 Compiled statistics 
Four out of the 13 sources mention compiled statistics, such as data from the 
‘Central Statistical Office’ [2], ‘health care system data’ [9] or national and 
regional health statistics [7] as a data source for modelling. These data may 
contain relevant information on demography, health behaviour or risk fac-
tors and they are the primary source to define all-cause mortality (from life-
tables). Additionally, they may provide information for costs, such as data on 
median income to calculate productivity costs. Before the data from those 
sources are used they have to be assessed in terms of quality and relevance 
for the model and their origin must be transparently stated.  
5.2.6 Expert opinions 
In the majority of the documents expert opinions are explicitly mentioned as 
a legitimised data source, especially in situations where data are missing, 
conflicting or insufficient. However, in a number of documents it is clearly 
stated that expert opinion is not accepted to define parameters related to ef-
ficacy or safety of a technology. One manual accepts expert opinion to define 
effectiveness on the basis of published data on efficacy, if no published data 
on effectiveness are available [10]. In the majority of the documents expert 
opinions are regarded as appropriate only for defining the model structure 
or to obtain qualitative information on the disease or the technology in ques-
tion while such data is regarded as hardly appropriate for defining final in-
put parameters. They may at most be a valid source for defining parameters 
that do not affect the results importantly [11].  
In any case, there is consensus across all manuals that the use of expert opin-
ions has to be justified and is only accepted as ‘last resort’ if no better data 
are available. Furthermore, all documents make clear that the use of expert 
opinions has to be described transparently (number of experts asked, selec-
tion process etc.) and opinions should ideally be derived via formal methods 
such as ‘Delphi’ or ‘Nominal Group techniques’. If parameters are defined on 
the basis of expert opinions they must undergo sensitivity analyses to con-
trol for uncertainty. Not least, it has been stressed that the collection of ex-
pert opinions may be a time-consuming task if done correctly [1].  
5.2.7 Further sources 
There are number of further data sources that are mentioned in the 13 re-
ports. These, firstly, include textbooks that may yield information on the 
doses of drugs, drug prices and reimbursement percentages[1]. Another 
source that is mentioned in three documents [1, 4, 6] are medical records 
that have the advantage of depicting the ‘real-life situation’ (e.g. for resource 
use information), although using them may be time consuming because their 
information cannot be entered directly into statistical data processing.  
Data from the consumer-price index and on purchasing power parities are 
mentioned as valuable source for inflating cost data and converting curren-
cies. Furthermore, official tariffs lists and lists on standard costs are men-
tioned as data source for cost calculation without providing further details 
on their characteristics.  
compiled statistics 
relevant for 
demography, health 
behaviour, mortality 
expert opinion is 
legitimate source for 
qualitative information, 
not for defining efficacy 
should be derived via 
formal and transparent 
methods 
further sources possible 
parentextbooks, medical 
records etc.paren 
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‘Finally, the Canadian manual [8] mentions clinical practice guidelines as a 
source for obtaining resource use data. 
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Table 5.2-1: Overview of information on how to parameterise models in guidelines and manuals 
 Weinstein et al. paren2003paren paren parenparen parenparen paren bracket11bracketbracket bracketbracket bracketbracket bracket Philips et al. paren2004parenparen parenparen parenparen parenbracket5bracketbracket bracketbracket bracketbracket bracket Nuijten paren1998paren paren parenparen parenparen paren bracket1bracketbracket bracketbracket bracketbracket bracket 
Recommended Method for 
data identification  
Systematic literature search; Searching should be systematic and efficient parenfocus on those 
parameters that are expected to have the largest influence 
on the model resultsparen; method of data identification needs 
to be transparent;  
Not stated 
Potential data sources as 
stated in the documents 
quoteall evidence may be legitimatequote parenincl. expert opinionparen; Clinical studies, epidemiological/observational studies, retro-
spective datasets, expert opinions, health statistics parene.g. life 
tablesparen, consumer price index, purchasing power parities;  
Clinical studies, meta-analyses, databases1, medi-
cal records, Delphi-methods, others parene.g. text-
books, official tariff listsparen; 
Required data characteristics Ranges parenie, upper and lower boundsparen should accom-
pany basecase estimates of all input parameters for 
which sensitivity analyses are performed.   
Data sources and results should not be rejected solely 
because they to not reach generally accepted probabil-
ity thresholds defining quotestatistical significancequote parene. g., p 
> .05paren; 
Best available data should be used for every parameter; 
clinical trial data should not always be regarded as the gold 
standard for modelling;  data can be incorporated as point 
estimates or as a distribution parenwill be influenced by how ana-
lysts evaluate parameter uncertainty;  
Not stated 
Recommendations on the 
correct handling of the data  
Expert opinion is a legitimate method for assessing pa-
rameters, provided either that these parameters are 
shown not to affect the results importantly or that a 
sensitivity analysis is reported on these parameters. 
Expert opinions need always be made transparent and 
should be derived from formal methods such as Delphi 
or Nominal Groups techniques; 
Quality and relevance of all data must be assessed; using ac-
cepted quality check lists is recommended;  
When using retrospective data, completeness of the data set 
should be assured including an assessment of the population 
covered by the data in comparison to that in the model; ret-
rospective data are a common source of resource utilisation 
estimates; 
if expert opinions are used, standards include documentation 
of the details of the inclusion criteria for experts, sample 
size, the types of questions asked, the method for data col-
lection and number of iterations; 
Hierarchy of data should be secondary to the identification 
of a hierarchy of parameters in the model;  
The strengths and weaknesses of each data source should be 
described; 
Not stated  
Advantages of single data 
sources 
Not stated Epidemiological/observational studies or the control group 
of an experimental study may be used to derive baseline 
probabilities on the natural history of a disease; 
It is often appropriate to derive relative risks parenor odds ratiosparen 
between treatment options in trials and to superimpose 
those onto baseline probabilities derived from other sources 
Meta-analyses: may be used in the definition of 
transitional probabilities parenbased on efficacy 
measures for initial treatmentparen parene.g. when the 
comparator in a pharmacoeconomic analysis is 
not the same as the comparator in a clinical 
trialparen; may provide data on treatment failure;  
                                                                      
1 refers to „claims databases and clinical outcome databases” 
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parenwhich are usually population basedparen; Databases: may contain a lot of detailed infor-
mation on both, clinical and economic outcomes 
for large number of patients; high external valid-
ity;  
Delphi Panel technique: appropriate in situations 
with missing, insufficient or conflicting data; 
Disadvantages of single data 
sources 
Not stated Clinical studies: low external validity, limited duration of fol-
low-up; 
Clinical studies: low external validity, units of 
health care that are used and collected may not 
be complete; often not powered to detect cost 
differences between groups and short follow-up; 
Meta-analyses: as clinical studies + risk of publi-
cation bias and inclusion bias; 
databases: rarely sufficient to draw definite con-
clusions about relative  effectiveness; format of 
information may not fit the structure of the 
model parene.g. coding of ICD-10 diagnoses driven by 
reimbursement issuesparen;  
medical records: information cannot be entered 
directly into statistical data processing parentime 
consumingparen;  
Delphi Panel technique: time-consuming; com-
promise between scientific rigour and need for 
structural information; 
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 Austrian HTA manual paren2011paren paren parenparen parenparen paren bracket7bracketbracket bracketbracket bracketbracket bracket IQWIG modelling manual parenparenparenparenGermanyparen paren2009paren paren paren parenparen paren parenparen paren paren
bracket3bracketbracket bracketbracket bracketbracket bracket 
NICE parenEnparenparenparen gland/Walesparen paren2008paren paren paren parenparen paren parenparen paren paren bracket12bracketbracket bracketbracket bracketbracket bracket KCE parenBelgiumparenparenparen paren paren2008paren  paren paren parenparen paren parenparen paren paren bracket4bracketbracket bracketbracket bracketbracket bracket 
Recommended method for data 
identification  
Not stated Systematic search For all parameters a systematic considera-
tion of possible sources is required, and 
the selection of sources to justify a par-
ticular outcome must be avoided;  
Systematic literature search for 
identifying clinical studies;  
Potential data sources as stated in 
the documents 
Clinical studies, prognostic studies, 
risk factor studies, epidemiological 
observational studies, disease regis-
tries, studies on compli-
ance/coherence, claims data, na-
tional and regional health statistics, 
expert opinions;  
Clinical studies, epidemiological studies, proc-
ess databases parenProzessdatenbankenparen2, regis-
tries3,, compiled statistics4, expert opinions; 
 
Sources might include cohort-studies, ran-
domised trials parenhead-to-head trials in par-
ticularparen, meta-analyses, non-randomised 
trials, cross-sectional surveys, national 
data based on healthcare resource groups 
parenHRGparen, public price list; 
 
Clinical studies, validated data-
bases, literature parenpeer-reviewed, 
no slides from presentations or 
abstractsparen, prospective observa-
tional studies, databases, patient 
charts, reimbursement scheme, 
quoteFOD Volksgezondheit/SPF SantZ 
Publicquote, expert opinions parennot ac-
cepted for defining probabilities or 
outcomes, if this information is 
available from published litera-
tureparen;   
Required data characteristics Not stated Depends on model parameter;   For continuous variables mean values 
should be presented; for all variables 
measures of precision should be detailed; 
Data should be presented with 
their 95% confidence or credibility 
interval; 
Recommendations on the correct 
handling of the data  
Selection of data needs to be justi-
fied; data on efficacy should be 
from clinical studies, on test accu-
racy of a diagnostic test from diag-
nostic studies, on prognostic pa-
rameters for morbidity and mortal-
ity from prognostic studies, on inci-
dences of future events from risk 
factor studies, on the frequency of 
events from epidemiological studies 
or disease registries, on therapy ad-
herence/coherence from studies on 
coherence/adherence, on resource 
utilisation from routine data/claims 
data, on demographic parameters 
from official health statistics; miss-
Required level of evidence depends on model 
parameter parene.g. data on efficacy require high 
level of evidenceparen; 
Clinical studies: pooled data or meta-analyses 
may be used;  
Epidemiological studies: interpretation of 
predictive functions and validity of transfer-
ring fixed risk functions to the modelled 
population need to be explained and justified; 
Process databases: relevance of its data for 
modelling needs to be assessed; 
Registries: access must be guaranteed and 
relevance of registry-data for model must be 
assessed;  
Compiled statistics: sources need to be stated; 
As much detail as possible on the data 
used in the analysis should be provided; 
Estimates of treatment effects should be 
based on the results of the systematic re-
view; 
Individual patient data are preferred, if 
available, for the estimation of subgroup-
specific parameters; 
Models should be based on data 
from clinical studies comparing 
the study medication and the 
comparator, on data from vali-
dated databases and/or data from 
literature; use of health state val-
ues from different clinical studies 
should be treated with caution 
parenonly if measured with same in-
strument and in similar popula-
tionparen; use of expert panels is sub-
ject to specific conditions; pref-
erably only as complementary 
source parenmethod described in detail 
in the manualquotes appendixparen; 
Manual refers to ISPOR model-
                                                                      
2 Databases that are derived from routine processes (Abrechnungsdatenbanken) 
3 Observational studies that systematically collect (a limited number of) data from a large number of patients who have been treated under routine conditions 
4 Health statistics that have been compiled by governments from census or survey data  
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ing data may be obtained from ex-
perts if controlled for uncertainty in 
sensitivity analyses; 
quality and relevance needs to be assessed; 
Expert opinions: Justification for and descrip-
tion of method used to obtain expert opinions 
needs to be stated;  
ling-guideline for further quality 
issues bracket11bracket; 
Advantages of single data sources Not stated Observational studies: appropriate for ex-
trapolation of clinical study-data and for iden-
tification of valid surrogate endpoints for pa-
tient relevant endpoints;  
Process data bases: contain data on large 
number of patients; appropriate if relevant 
target population in model is sufficiently de-
picted in the data parenvia diagnostic codesparen; help-
ful for defining treatment paths, behaviour of 
patients parenfor cost calculationparen; 
Registries: represent real-life situation; may 
be helpful for defining predictive functions 
that describe the association between clinical 
event and resource use, quality of care, sick 
leave etc.; 
Compiled statistics: may contain information 
on demography, health behaviour and risk 
factors; useful to define all-cause mortality; 
Expert opinions: restricted use for defining 
the model structure and assumptions; 
Not stated Meta-analyses of clinical trials 
may increase the reliability of the 
clinical evidence and thereby va-
lidity of the model;  
Disadvantages of single data 
sources 
Not stated Clinical studies: for cost estimates only of re-
stricted value parene.g. incomplete information on 
issues of care that may be relevant for total 
costs, not enough power to detect cost differ-
encesparen;  
Process databases: problematic if the defini-
tion of the model population includes pa-
rameter parene.g. clinical results, specific patient 
characteristicsparen that are not coded in the da-
tabase;  
Expert opinion: for defining final input pa-
rameters hardly ever appropriate; 
Trial data may not be sufficient to quan-
tify baseline risk; 
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 Poland Agency for HTA paren2009paren  paren parenparen parenparen paren bracket13bracketbracket bracketbracket bracketbracket bracket CADTH  parenparenparenparenCanadaparenparen2006paren parenparen parenparenparen parenparenparen paren bracket8bracketbracket bracketbracket bracketbracket bracket 
Recommended method for data 
identification  
Systematic search for key parameters; For key parameters: systematic search; non-systematic search needs to be jus-
tified;   
Potential data sources as stated in 
the documents 
Clinical studies, observational studies, routine databases, list of standard costs, 
published literature;  
RCTs, observational studies, administrative databases, disease registries, ex-
pert opinions, standard cost lists, clinical practice guidelines, systematic re-
views and/or meta-analyses, administrative and accounting data;  
Required data characteristics Not stated Data can be incorporated as point estimates or as distribution parenin case of 
probabilistic sensitivity analysisparen; 
Recommendations on the correct 
handling of the data  
If expertsquote opinions are the source of input data, the methods of obtaining the 
data should be described; 
All data should be reported and their sources identified; details of the data 
should be described parene.g. from which data were derived and to which the re-
sults applyparen; data limitations should be made transparent and the methods for 
handling them described;  
Manual refers to Philips et al. bracket5bracket and Weinstein et al parenISPOR documentparen bracket11bracket 
for further quality issues; 
Advantages of single data sources Results of effectiveness obtained from observational studies are better than ex-
perimental results assessed in a systematic review, which should be treated with 
utmost care; 
Systematic reviews and meta-analyses can produce high quality data for 
model parameters, and add to the credibility of economic evaluations; they 
also provide useful information for analysing uncertainty surrounding the 
relevant estimates; 
Disadvantages of single data sources Not stated Not stated 
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 Alves de Silva et al. parenPortugalparen paren1998paren paren paren paren parenparen paren paren parenparen paren paren paren
bracket10bracketbracket bracketbracket bracketbracket bracket 
Szende et al. parenHungaryparen paren2002paren paren paren paren parenparen paren paren parenparen paren paren paren bracket2bracketbracket bracketbracket bracketbracket bracket AMCP parenUSAparen paren2009paren paren paren paren parenparen paren paren parenparen paren paren paren bracket14bracketbracket bracketbracket bracketbracket bracket PHARMAC parenNew Zealandparen paren2007parenparen paren paren parenparen paren paren parenparen paren paren paren 
Recommended Method for data iden-
tification  
Not stated Systematic search for effectiveness systematic search for key model pa-
rameters 
quoteAll evidence should be obtained system-
aticallyquote 
Potential data sources as stated in the 
documents 
Clinical studies and meta-analyses, 
population-based epidemiological stud-
ies, hospital-based epidemiological 
studies, expert panels;  
Large scale real-life RCTs or sys-
tematic reviews, clinical studies, 
non-experimental studies, expert 
opinions, data from the Informa-
tion Centre for Healthcare, data 
from Central Statistical Office; 
RCTs, observational studies, health 
care system data, expert opinions; 
Effectiveness: published RCTs, meta-
analyses and observational studies; un-
published data from clinical studies; ex-
pert opinions; data from medical records 
and case reports;  
All-cause mortality: life tables; 
Long-term outcomes: observational stud-
ies or other clinical studies; 
Costs: Pharmaceutical Schedules, clinical 
studies parenfor dosesparen, Health Information 
Service;  
Utility values: several databases on 
health-related quality of life data;  
Required data characteristics Not stated Not stated  Not stated 
Recommendations on the correct han-
dling of the data  
For the epidemiology of a disease: 
population-based epidemiological stud-
ies should be used; if such data are un-
available, hospital-based or regional 
epidemiological studies may be used; 
For effectiveness: RCTs or meta-
analyses on efficacy are to be preferred 
parenadapted with data on effectiveness dash 
e.g. from observational studiesparen; 
Prospective data are to be preferred in 
contrast to retrospective data;  
Expert panels should be considered as 
last resort and cannot be used to esti-
mate efficacy parenonly effectiveness on 
the basis of real efficacy data or for dis-
eases, syndromes or conditions with a 
low prevalence or incidenceparen; 
Data on the current medical practice 
can be derived from epidemiological 
studies or cross-sectional studies;  
 
Ideally, effectiveness data should 
be derived from large, randomised, 
real-life, cost-effectiveness studies 
and their systematic reviews; in 
practice, these rarely exist -
>alternative sources are required; 
Expert opinion is not substitute for 
sound evidence but may help to in-
terpret the outcomes of the stud-
ies, to frame the context and to 
predict resource utilisation pat-
terns;  
Cost data should be derived from 
the quoteInformation Centre for health 
carequote, average salary values should 
be taken from quoteCentral Statistical 
Officequote;  
For efficacy and effectiveness: RCTs, 
for safety: RCTs and observational 
studies; economic and demographic 
parameters: health care system data; 
expert opinions are not generally ac-
ceptable, esp. For key effectiveness or 
safety variables;   
Not stated 
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Advantages of single data sources Not stated Not stated Not stated RCTs: external influence minimised -> ef-
fect is attributable to intervention alone; 
Meta-analysis: useful when results con-
flict between trials, when inappropriate 
comparators are used or when a trial con-
sists of only one treatment arm; single 
trial may be insufficiently powered; 
Observational studies: high real world 
relevance; allow observation of treatment 
on compliance and treatment switching 
patterns; 
Expert opinion: clarification of unreliable, 
conflicting or insufficient clinical informa-
tion in the literature;  
Case reports and medical records: high 
real world relevance;  
Disadvantages of single data sources Not stated Not stated Not stated RCTs: poor external validity; often short 
time spans; may be subject to publication 
bias;  
Meta-analysis: publication and inclusion 
bias; may be difficult to assess validity; 
incompatible trials may be included;   
Observational studies: lack of control 
over confounding factors; underlying bi-
ases; lack of control group; 
Expert opinion: subject to selection bias; 
Case reports and quotemedical recordquote: high 
risk of bias; small patient numbers; 
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6 Standards for data identification  
As outlined in table 5.2-1 the standard method for identifying data in pub-
lished literature is the systematic (in contrast to selective) literature search 
which is mentioned in every manual that describes how to obtain data. The 
reason behind the systematic search is to minimise (selection) bias as much 
as possible.  
However, the documents vary in the extent to which various model parame-
ters need to be based on systematic literature search. By referring to re-
source constraints, several manuals limit the requirement for a systematic 
search to ‘key model parameters’. While it has usually not been defined 
which parameters are to be seen as ‘key parameters’, parameters on efficacy 
or effectiveness are mentioned in most of the documents as those for which 
data must be obtained via systematic search. Philips et al. [5] define the ‘key 
parameters’ as those that are expected to have the largest influence on the 
model results.  
Furthermore, Philips et al. [5] offer a comprehensive overview on valid data 
sources for a variety of parameters (baseline event rates, health-related 
quality of life and its valuation, resource use and unit costs, relative treat-
ment effects, other parameters). Moreover, they provide guidance to define 
‘searchable questions’ and (in the appendix of their document) they present 
search strategies for various parameters from a case-study. The approach is 
not different from systematic search techniques known from HTA-manuals. 
Generally, all documents agree on the standard to present the search for any 
model data transparently and to state the sources used. The exclusion of 
(appropriate) available and known data sources needs to be explicitly justi-
fied.  
Some manuals point out that a systematic search does not guarantee to 
avoid all sorts of bias. The main problem arises if studies have been pub-
lished selectively in the first place (publication bias).  
 
systematic literature 
search is standard for 
data identification 
resource constraints 
may limit systematic 
search to key 
parameters 
good guidance in Philips 
document 
search for any data 
needs to be transparent 
no guarantee for 
avoiding any bias 
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7 Recommendations on the correct  
handling of data 
While the documents agree on the requirement to use the best available data 
for every parameter, some also make clear that not every parameter re-
quires data from highest level in the evidence hierarchy (RCTs or meta-
analyses). As Philips et al. [5] point out, the hierarchy of data should be sec-
ondary to the identification of a hierarchy of parameters in the model. In 
other words, clinical trial data should not be regarded as the gold standard 
for every single model parameter.   
Concerning potential data sources for key model parameters, the following 
recommendations can be summarised from the documents (see also table 
5.2-1): 
b Firstly, parameters that deal with the efficacy, effectiveness or safety 
of a treatment/preventive measure need to be based on data that are 
at the highest level of the evidence hierarchy (RCTs or meta-analyses). 
However, both safety and effectiveness data may also be obtained 
from observational studies/disease registries as they represent the 
real-life situation better than clinical trials.  
b Secondly, parameters that are related to baseline probabilities and to 
the natural history of a disease may be derived from observational 
studies/disease registries or from the control group in clinical studies. 
b Observational studies are also a potential source to parameterise 
long-term effects (for extrapolating data from clinical trials). 
b Data on health related quality of life and their valuation are primarily 
to be obtained by primary data collection or from existing national 
data (e.g. on health state valuation). Two documents provide secon-
dary data sources for those data, however limitations in terms of 
transferability have been stressed and caution has been pointed out 
when combining health related quality of life data and/or their valua-
tion from various sources. 
b Parameters on demographic characteristics (including all-cause mor-
tality) can be derived from national health statistics. For defining all-
cause mortality, life-tables are recommended in various manuals.  
b Data on resource use as well as on unit costs need to be context-
specific and will therefore hardly be found in published literature. Ap-
propriate data sources for the former will rather be routine data, 
clinical practice guidelines and expert opinions. Published clinical 
studies may in some cases be a potential source of information for re-
source use patterns, although severe limitations in terms of transfer-
ability from one jurisdiction to another or from the study-context to 
the real-life context need to be taken into account.  
b Where data sources on unit costs have been described in the docu-
ments, they are also rather country-specific such as standard price 
lists or national data on health care resource groups.  
Three documents [5, 11, 12] present details on required data characteristics. 
For example Weinstein et al. [11] points out that ranges (ie, upper and lower 
bounds) should accompany basecase estimates of all input parameters for 
which sensitivity analyses are performed. Similarly, the NICE guideline [12] 
hierarchy of data should 
be secondary to 
hierarchy of model 
parameters 
recommendations: 
high level of evidence 
for efficacy, 
effectiveness and safety: 
RCT, meta-analysis 
Baseline 
probabilites/data on 
natural history from 
observational 
studies/registries 
quality of life data from 
primary research or 
parenwith limitationsparen from 
published clinical studies 
demographic data from 
national statistics 
resource use and cost 
data from routine data, 
practice guidelines and 
expert opinions 
data should be 
presented with upper 
and lower bounds 
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states that for continuous variables mean values should be presented and 
that for all variables measures of precision should be detailed. Finally, data 
sources and results should not be rejected solely because they to not reach 
generally accepted probability thresholds defining ‘statistical significance’ (e. 
g., p > .05). 
Overall, the methodological guidelines stress that data have to be assessed in 
terms of relevance and quality before they are used for defining model pa-
rameters. For quality assessment specific quality checklists that exist for 
various types of data (e.g. data from clinical trials, data from cohort studies) 
are recommended. In any case, data limitations and how these were dealt 
with (e.g. by applying different types of sensitivity analyses) need to be de-
scribed transparently.  
 
 
 
quality assessment  via 
checklists required 
before using data for 
models 
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8 Conclusion of literature search 
Concerning parameterising decision analytic models, three different subjects 
have been addressed in the previous chapters: Firstly, generally available 
potential data sources to define model parameters have been identified. Sec-
ondly, standards on how to identify or search for those data have been 
summarised and thirdly, recommendations on the correct handling of such 
data have been presented.  
Data identification and choosing appropriate data considerably contribute to 
the overall quality of parameters used in a model. In other words, adhering 
to standards in choosing appropriate data sources and in the further proc-
essing of data will greatly improve the quality of model parameters and, 
hence, the quality of the model per se.  
Generally, it needs to be noted that the terminology used for the different 
types of data lacks consistency and due to the absence of clear definitions of 
the terms used it has not always been clear what type of data the authors are 
exactly referring to. For example clinical studies and observational studies 
are mentioned as two different data sources [7]. However, observational 
studies may also be defined as a subtype of clinical studies. It has become 
clear that in many cases authors use the term ‘clinical studies’ when they 
mean randomised controlled clinical trials (that is experimental clinical 
studies).  
The research questions from chapter 2 can be answered in the following 
way:  
The primary data sources for model parameters in the literature are RCTs 
and meta-analyses for efficacy, effectiveness and safety issues. Various types 
of (clinical) epidemiological studies are appropriate for effectiveness and 
safety issues, for data on the natural history of disease, for long-term effects 
and for epidemiological data (e.g. mortality rates, life-expectancy).   
Additionally, a number of further sources of secondary data have been men-
tioned, being routine data and national statistics. Finally, expert opinions 
have been addressed throughout all manuals, however, with pointing out 
their limitations.  
Secondary data from published literature that are used for parameterising 
models, should as much as possible be based on systematic literature 
searches. Yet, the limitations in resources have been acknowledged and sug-
gestions have been made to restrict the systematic search to efficacy data 
and to those data that are used for model parameters that are likely to have 
the largest influence on the result. The technique of the literature search 
does not differ from standards in literature search in HTA general. 
The manuals do not address the issue of using primary data from published 
clinical studies, however, there are examples elsewhere, where such data 
have been used and pooled for further research purposes such as the ‘Cho-
lesterol Treatment Trialists Collaboration’ [15]. 
With respect to required data characteristics, the manuals provide very lim-
ited information. Yet, it has been mentioned in several documents that 
ranges are required for those data that are later on used for sensitivity 
analyses in the model.  
three subjects 
addressed: data sources, 
data identification, data 
processing 
quality of model  
depends on correct 
identification and 
handling of data 
terminology of data 
sources in manuals not 
always clear 
core secondary data 
sources: published RCTs 
and meta-analysis, 
further clinical studies 
further secondary data 
sources and expert 
opinions also relevant 
data from literature 
should be based on 
systematic literature 
search  
method like in HTA 
using primary data from 
published clinical studies 
not addressed but 
possible 
limited information on 
specific data 
characteristics 
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The manuals do not address the issue of using published literature for quali-
tative information on the model. Qualitative information has, however been 
mentioned in context with expert opinions where qualitative rather than 
quantitative information may be obtained.  
Questions no. 1 and 4 (type of data that are available from clinical studies; 
can data from clinical studies be obtained in a less aggregated way as pre-
sented in the publication) will be addressed in the following chapters. 
 
 
Dealing with qualitative 
information from 
published literature not 
addressed  
open questions will be 
dealt in part two of 
report 
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9 Applying the methodological standards to  
quoteHPV-vaccination modellingquote 
In the previous chapters it has been shown that a variety of data sources are 
needed to define model parameters appropriately. While many of those in-
clude secondary published literature, several further secondary data sources 
(such as routine data) have been mentioned in the manuals.  
In the remainder of the report, the information from the previous sections 
on potential data sources will be applied to the case of ‘HPV-vaccination 
modelling’ for using it later on in work package 8.  
The following sections will systematically describe the information catego-
ries that are relevant for the planned modelling exercise. In relation to ap-
propriate data sources from chapter 5, potential data sources for the ‘HVP-
vaccination model’ will be identified and data that are considered as relevant 
will be extracted. Data extraction will, however, be restricted to secondary 
published literature whereas data that from other secondary data sources 
will not be addressed. Readers are referred to work package 5 for further in-
formation on the latter. Finally, the relevance and limitations of the data 
identified will be discussed and the overall process and the experience 
gained will be contrasted with the methodological standards obtained from 
the manuals in the previous chapters. 
Where appropriate, literature that has already been identified via literature 
search in a 2011 updated ‘HPV-vaccination project’ at the LBI-HTA (see 
http://hta.lbg.ac.at/de/projekt_detail.php?iMenuID=66&iProjectID=28) will 
be used as source for data. These sources include published studies until July 
2011. Only in those cases where additional literature is required, there will 
be a separate literature search. For reasons of resource constraints, this will, 
however, not be a systematic search but it will rather be restricted to a basic 
search for most recently published studies, reviews or meta-analyses in Pub-
Med. This is because the aim of this chapter is to provide examples for the 
type of data and their characteristics as they can be found in the literature 
rather than a full overview of published secondary data for every single 
model parameter. Furthermore, due to resource constraints the studies will 
not be assessed for quality. 
9.1 General overview on the HPV-modelling 
concept for work package 8 
HPV-vaccination has been introduced in numerous countries with the aim to 
prevent HPV-infection from two to four HPV-types and diseases that are re-
lated to persistent HPV infection. 
The aim of the modelling exercise in work package 8 is to update the disease 
model on HPV-infection that has been used by the LBI-HTA in 2007 [16] with 
the latest epidemiological evidence, with evidence on the efficacy of the vac-
cination and on sexual behaviour. Furthermore, the model will be used to 
compare HPV-vaccination with additional screening alternatives and to pre-
dict additional health outcomes and costs. 
several secondary data 
sources required for 
models 
standards from manuals 
will be applied to HPV-
vaccination case study 
required information 
categories will be 
described and data for 
those will be identified 
in the literature 
further secondary data 
not addressed 
literature from earlier 
projects will be used 
 
data will not be assessed 
for quality 
HPV-vaccination 
introduced in several 
countries 
in WP8: update of 
earlier HPV-vaccination 
model 
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The following alternatives will be analysed 
b Screening only ‘status quo’5 
b Screening only ‘status quo’ + HPV-vaccination of 12-year old girls 
b Screening only ‘status quo’ + HPV-vaccination according to Austrian 
vaccination recommendations6 
b Screening only ‘new’7 
b Screening only ‚new’ + HPV-vaccination of 12-year old girls  
b Screening only ‚new’ + HPV-vaccination according to Austrian vaccina-
tion recommendations 
 
The following outcome parameters will be analysed 
b clinical parameters 
b cervical carcinoma incidence 
b cervical carcinoma mortality 
b precancerous lesions (and the number of conisations that are 
linked with them) 
b life years gained 
b economic parameters 
b incremental costs (direct costs only) 
b incremental cost-effectiveness ratios 
b budget impact 
The model should enable future work to develop an overall appropriate pre-
vention strategy on cervical cancer in Austria considering different preven-
tion alternatives.  
Based on the previous work on HPV-vaccination modelling in Austria, a 
number of data categories and specific data requirements have been identi-
fied that will be described in the following sub-chapters.  
9.2 Demographic data 
Demographic data are required for defining the size of the various age co-
horts that are to be vaccinated and screened over the defined time horizon 
and for linking the dynamic of the Austrian population with the transmission 
                                                                      
5 Status quo is related to current practice in terms of screening interval, opportunistic 
screening and diagnostic procedures 
6 Vaccination of girls and boys at the age of 9 years, catch-up boys until 15 years and 
girls/women until 26 years  
7 Increased screening participation based on experience in countries with well-
running organised screening; screening (80%); interval according to guidelines and 
experience in countries with organised screening (3 to 5 years); adapted age-group 
according to European Advisory Group on Cancer Prevention: 25-65 years and ac-
cording to Austrian ‘Vorsorge Neu document’: 21-69 years; organisation of pap-
smear taking and quality control according to European guideline;   
alternatives compared 
in the model 
outcome parameters 
addressed 
model is basis for 
further work on cancer 
prevention 
demographic data need 
to be identified in 
national statistics 
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dynamic of HPV-infection. Furthermore, they are needed for calculating life 
years gained based on age-specific mortality in Austria.  
Since these data need to be identified in national statistical data rather than 
in published literature, they will not be addressed in more detail in this re-
port (for information on the data used in the model in 2007 see the accord-
ing report  [16]). 
9.3 Epidemiological data 
The model addresses the impact of different prevention/screening strategies 
on HPV-infection, on precancerous lesions related to cervical carcinoma and 
on invasive cervical carcinoma. Hence, data are needed that provide infor-
mation on the characteristics of the diseases under consideration.  
9.3.1 Data on the natural history of the disease 
First of all, detailed quantitative and qualitative information on the process 
of HPV-infection and on the subsequent process of developing persistent in-
fections and finally, precancerous lesions and an invasive carcinoma is re-
quired. This includes various types of information, being the time period be-
tween infection and precancerous lesions or between lesions and invasive 
carcinoma, the risk factors for infection and further progression (or regres-
sion) of the disease, the transmission patterns of the virus (virus types, risk 
of transmission per sexual contact etc.), the patterns of natural immuno-
genicity and the probabilities for transition and regression between the 
various stages of the disease.  
According to chapter 7, parameters that are related to the natural history of 
a disease may be derived from observational studies/disease registries or 
from the control group in clinical studies.  
Because of ethical reasons very few studies exist that have observed the 
natural history of disease from HPV-infection ->persistent infection -
>precancerous lesion ->invasive carcinoma and the possible regression (e.g. 
infection to clearance of infection). Existing studies are from time periods 
before screening methods and treatment options became available. For the 
same ethical reasons, subjects in RCT-control groups will immediately be 
treated if they develop precancerous lesions. Hence, the progression pat-
terns to invasive carcinoma or the regression to less severe stages are un-
known in these women.  
Not surprisingly, it became apparent that because of the few and quite out-
dated observational studies that are available the same rare sources are 
used in a number of published papers and reports on issues related to HPV 
and cervical cancer. For example the suggested regres-
sion/persistence/progression likelihoods of pre-cancerous lesions by Östor 
[17] are cited by the European Commission guideline on cervical cancer 
screening [18], by an HTA on Screening [19] or by patient information mate-
rial on screening and vaccination [20, 21].  
For efficiency reasons the search for the vast variety of data was restricted to 
identifying reliable and evidence based overview documents. One document 
not covered in this 
report 
data on characteristics 
of HPV-infection, 
precancerous lesions 
and cervical cancer 
required 
process infection -> 
cancer includes various 
types of information 
observational studies 
may be relevant source 
because of nature of 
disease and treatment 
few such studies 
available 
same data have been 
used by many study 
authors 
reliable overview 
document was identified 
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that seems to provide extensive and evidence based information is a descrip-
tion of cervical cancer screening that has been developed for patient infor-
mation purposes and includes data on the natural history of infection and on 
the development of cervical cancer [20]. Table 10.3-1 gives an overview on 
the data that are presented in this document.  
Table 9.3-1: Information overview on the natural history of disease based on [20] 
Time period between infection and invasive carcinoma 15 to 30 years 
Time period between infection and precancerous lesion 10 years 
Time period between precancerous lesion and invasive carcinoma > 10 years 
Proportion of infected who develop antibodies 50 % to 60 % 
Proportion of simultaneous infection with more than one HPV-type  20 % to 30 % 
Proportion of infections that clear within 2 years more than 80 % 
Proportion of infections that clear within 3 years more than 90 % 
Proportion of women who develop precancerous lesions after persistent 
HPV-16 infection after 3 to 5 years 
40 % 
Risk factors that are associated with precancerous lesions infection with more than one virus-type, 
high virusload, immunosuppression, 
smoking, oral contraceptives 
Risk increase in women who take oral contraceptives between age 20 and 30 3.8 to 4.5 times per 1000 women 
Percentage of women with CIN 3 or CIS parencarcinoma in situparen who develop in-
vasive carcinoma in 5 to 10 years 
20 % to 30 % 
Regression rate for CIN1 to CIN 3 in 18 to 34 year old women 85 % 
Regression rate for CIN 1 to CIN 3 in quoteolder womenquote 19 % to 60 % 
 
Additionally, the document presents a table on the regression and progres-
sion across different precancerous lesions that is based on several literature 
sources (see table 10.3-2).  
Table 9.3-2: Estimated frequency for regression, persistency and progression between dysplasias 
without treatment based on different literature sources [20] 
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Concerning the HPV transmission patterns, a recent meta-analysis of HPV in-
fection concordance has been identified that may be useful [22]. As for ex-
ample shown in table 10.3-3, the paper presents the expected and observed 
HPV concordance (defined as both partners having the HPV outcome of in-
terest).  
Table 9.3-3: Expected and observed type-specific HPV concordance [22] 
 
 
Apart from quantitative information, qualitative information on the natural 
history of disease will be required to better understand the whole disease 
process. A useful starting point for this type of information is provided by 
Schiffman et al. [23] and by Bosch et al. [24].  
9.3.2 Data on the frequency of HPV infection, 
precancerous lesions and invasive cervical 
carcinoma 
Data on the epidemiology of HPV-infection and on the occurrence of precan-
cerous lesions and invasive carcinomas including information on the distri-
bution of HPV genotype in those cases in Austria are needed. 
The primary source for this kind of data would be national disease and can-
cer registries, however, they may not hold detailed enough information. For 
example, data on the type of precancerous lesion (CIN 1 to CIN 3) or on the 
associated virus genotype will be needed for the disease model, but the na-
tional cancer registry only provides data on the number of newly diagnosed 
invasive carcinomas and on the number of women who died from cervical 
carcinoma per year disaggregated by cervical cancer stage. Hence, additional 
published literature needs to be searched for more detailed information. 
Possible study types from which this kind of information may be extracted 
include prevalence surveys about the HPV type-specific burden of cervical 
cancer, population based surveys on the cervical HPV prevalence, specific 
observational studies in clinical epidemiology such as cohort studies, case-
control or cross-sectional studies and randomised controlled trials.  
meta-analysis on HPV 
infection concordance 
may be useful for info 
on transmission 
patterns 
Austrian data on HPV 
infection and 
epidemiology of its 
consequences needed 
national disease/cancer 
registries provide only 
limited information 
Possible study types: 
parenpopulation based paren paren
surveys on HPV 
prevalence, clinical 
studies 
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HPV infection 
Concerning the prevalence of HPV-infection in females, a meta-analyses on 
cervical HPV prevalence in 5 continents [25] and an analysis on the Austrian 
HPV 6, 11, 16 and 18-prevalence among women that participated in a vacci-
nation RCT [26] were available.  
The data characteristics of these two studies are presented in table 10.3-4. 
The Austrian study yields only limited information on the overall prevalence 
of 4 HPV types (against which the quadrivalent vaccination has been devel-
oped) in 111 study subjects.  The information is further restricted by the fact 
that prevalence data are from females in young age (16-24 years) only.  
On the contrary, the meta-analysis on the worldwide HPV-prevalance pro-
vides more detailed data on the prevalence of the most frequent HPV-types. 
Although studies from Western European countries have been included, 
none of them is from Austria. Furthermore, the age-specific data are pre-
sented in a figure without detailed quantitative information on every single 
age-group. For the latter the reader is referred to online-tables.  
Table 9.3-4: Data characteristics in published studies on genotypes in HPV-infection 
Study author/year Six et al. bracket26bracket/2008 Bruni et al. bracket25bracket/2010  
Countries addressed Austria 5 continents 
Within Western Europe: Belgium, France, Germany, Switzer-
land, Netherlands 
Age groups analysed 16-24 ; mean: 19.9 parenSD: 1.7paren ≤ 25 to > 64 years 
Race/ethnicity  100% white Not stated 
Genotypes addressed 6, 11, 16, 18 Any HPV type 
No of subjects studied 111 parenAustrian sample of a 
European multi-centre RCTparen 
1,016,719 women with normal cytological findings; Western 
Europe: 77,445 
Results 15 paren13.5%paren were positive of 
HPV 6, 11, 16, or 18 
Highest prevalence: HPV-16 
paren11.4 %paren 
HPV-18: 3.5 % 
World HPV-prevalence crude: 7.2% paren7.1-7.2paren; adjusted¤: 11.7% 
paren11.6-11.7paren 
Western Europe crude: 7.3% paren7.1-7.5paren; adjusted: 9.0% paren8.8 dash 9.2paren 
World high-risk crude: 5.5% paren5.5-5.6paren; adjusted: 5.0% paren5.0-5.1paren 
Europe most frequent HPV-types: 
16: 4.8%; 31: 2.3%; 18: 0.9%; 39: 0.8%; 33, 66: 0.6%; 6: 0.5%; 
45, 52, 51, 58: 0.4; 53, 56, 70, 11: 0.3%; 42, 81, 68, 83, 59, 61, 35: 
0.2%; 73, 44, 90, 72, 62, 69, 54: 0.1%;  
Decreasing prevalence over time; highest prevalence in < 25 
years, then declining until 54 years and again rising in age ≥55 
Comment by study au-
thors 
Overall rate of positive 
HPV-genotype in Austrian 
sample is lower than in 
European participants of the 
trial paren25.3 %paren in women 
with normal cytology but 
similar in those with ab-
normal cytology 
HPV-31 is very common in Europe paren2nd rank after HPV-16paren but 
much less in Northern America or Asia; 
Heterogeneity caused by different HPV-detection methods and 
by the selection and representativeness of the population is a 
problem 
SD: standard deviation; ¤: standardised by the world’s geographical structure; adjusted 
by geographical region, mean age of women, ending year of study, HPV testing 
method, proportion of high-risk HPV-types tested, proportion of low-risk HPV 
types tested, and cluster (analysis of mixtures);  
meta-analysis and 
Austrian trial analysis on 
HPV-infection in 
females 
data characteristics 
summarised in table 
no Austrian data in 
meta-analysis 
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In terms of HPV-infection in males, a cohort-study on the incidence and 
clearance of genital HPV infection in men in the USA, Brazil and Mexico [27] 
has recently been published. This type of information on HPV-infection in 
males has not been available when the LBI-HPV vaccination modelling exer-
cise has been done in 2007.  
In the publication, detailed information on the baseline characteristics of the 
study group and on the results are provided in two tables (see table 10.3-5 
on the study results).  
The results on the incidence per 1000 person months, on the 12-months in-
cidence and on the median time to clearance of an infection include the point 
estimates as well as the 95% confidence intervals. Further data that are pre-
sented in the result table are on the prevalence (absolute and in %), on inci-
dent infections, on person months, on new infections and on cleared infec-
tions. Furthermore, the study presents 8 Kaplan Meier estimates of the cu-
mulative incidence and time to clearance of any, type 16, oncogenic, and 
non-oncogenic HPV infections by age.  
The authors point out that the results on incidence cannot be generalised to 
all men in the three countries studied whereas the assessment on factors as-
sociated with HPV acquisition and clearance are less prone to bias.  
As confirmed by the WHO report on HPV, specific data on the HPV preva-
lence in males in Austria are not available [28]. 
cohort-study on HPV-
infection in males 
data characteristics are 
presented in table 
results only partly 
generalisable 
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Table 9.3-5: Prevalence, incidence and clearance of HPV infection in men [27] 
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Precancerous lesions and cervical cancer 
In addition to national or regional cancer registries, data on the Austrian 
cervical cancer epidemiology can also be identified in published literature. 
Although these data are again from cancer registries or from other secon-
dary sources (e.g. from the WHO database) they may yield additional and 
more detailed information that is not directly accessible from registries. One 
data source is a WHO report on HPV and cervical cancer in Austria [28].  
Incidence 
The report contains information on cervical cancer incidence in Austria 
compared to Europe and the world (see table 10.3-6) as well as comparative 
data on the incidence of cervical cancer disaggregated by Austrian cancer 
registry (see table 10.3-7). Furthermore, age-standardised rates on cervical 
cancer by histological type across the different registries and the annual 
number of new cancer cases by age-group are provided in the report (see ta-
ble 10.3-8 and figure 10.3-1). Data on precancerous lesions are not available. 
 
Table 9.3-6: Incidence of cervical cancer in Austria, Western Europe and the world [28] 
 
Table 9.3-7: Incidence of cervical cancer in Austria by cancer registry [28] 
 
 
some published sources 
on cancer epidemiology 
available 
Austrian incidence data 
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Table 9.3-8: Age-standardised incidence rates of cervical cancer by histological type and cancer registry in Austria [28] 
Figure 9.3-1: Annual number of new cases of cervical cancer by age-group [28] 
 
Mortality 
The same WHO report contains data on cervical cancer mortality in 
Austria, compared to Western Europe and the world and on the num-
ber of cervical cancer deaths by age-group in Austria (see table 10.3-9 
and figure 10.3-2). 
Austrian mortality data 
 LBI-HTA | 2012 37 
Table 9.3-9: Mortality of cervical cancer in Austria, Western Europe and the world 
[28] 
 
 
Figure 9.3-2: Annual number of cervical cancer deaths by age-group [28] 
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9.3.3 Data on HPV genotypes in HPV infection, 
precancerous lesions and invasive cancer cases  
The frequency of HPV genotypes in HPV infection has already been 
described in the studies that analysed HPV infection (see chapter 
10.3.2). Details are provided by Six et al. [26] for Austria, Bruni et al. 
[25] for the world regions and Giulinao et al. [27] for males. 
A recent study presents the HPV-type distribution in adenocarcino-
mas in situ that was observed in two phase 3 clinical trials of the 
quadrivalent vaccine ‘Gardasil’ [29]. Most of the women in the small 
sample analysed were from Europe (77% out of 22 subjects) and of 
white ethnicity. The study provides a table on the HPV DNA detected 
in AIS (adenocarcinoma in situ) lesions for every study subject ana-
lysed. The authors do, however, not present a summary table or a 
written summary on the overall HPV type distribution in AIS lesions. 
Only in the discussion, the authors mention that 96% of all AIS lesions 
were positive to HPV 16 or 18.  
It may be of use for the planned HPV-model that the paper contains a 
table on the time to detection of AIS, stratified by day 1 HPV DNA 
status and pap smear result.  
However, since the data are from a RCT study population, their valid-
ity is limited to persons with the demographic characteristics of the 
study population (e.g. mean age of 20.4 years). 
Concerning HPV genotype attribution in invasive cervical cancer, a 
recent retrospective cross-sectional study on the worldwide HPV 
genotype attribution [30] and a meta-analyses on published literature 
have been identified [31].  
In the former, paraffin-embedded specimens from cases (aged 16-97 
years) with cervical cancer were obtained from hospital archives in 
38 countries including 10 European countries (with 2058 specimens). 
Austria was not part of the study. Table 10.3-10 and table 10.3-11 
demonstrate the type of data that are presented in the study. These 
include the prevalence of 33 HPV genotypes analysed by region and 
histological type of cervical cancer. A third table yields information on 
the number and percentage of overall HPV positive cases, single HPV 
types and multiple HPV types by region. The authors refer to a web 
appendix that contains additional information, for example on the 
mean age of diagnosis. 
 
 
 
 
 
small study on 
HPV-types in 
adenocarcinomas 
in situ 
limited validity 
two large studies 
on HPV genotype 
distribution in 
invasive cervical 
cancer 
analysis of 
archived 
specimens in 38 
countries and… 
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Table 9.3-10: HPV genotypes in invasive cancer cases by region [30] 
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Table 9.3-11: HPV genotypes in invasive cancer cases, by histological diagnosis [30] 
 
The meta-analysis [31] includes 243 studies covering a total of 30,848 cases 
of invasive cervical cancer. 79 studies with 9,015 cases were from Europe in-
cluding Austria. The data in the publication yield information on the HPV 
types (overall, by histological type and by year of publication), on the HPV-
16 prevalence in invasive cervical cancer across strata of regions and on the 
ten most frequently detected HPV types from 1990 to 2010 by region. The 
latter, however, is presented in figures without detailed numerical informa-
tion. The limitations of the data are that the changing prevalence over time 
may also be due to changes in the sensitivity of the detection methods and 
the increasing prevalence of multiple infections complicates the estimation 
of proportions of cancer that can be attributable to groups of HPV types. 
…meta analysis of 
published studies 
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Additionally, the WHO-report on HPV and related cancers provides summary 
information on HPV-genotypes in Austria. However, the data are restricted 
to the distribution of HPV-genotypes in invasive cervical cancer (see table 
10.3-12 and figure 10.3-3). Data on the distribution of HPV-genotypes in 
precancerous lesions are not available. To a great extent the data in the re-
port are derived from the same sources as mentioned in the earlier para-
graphs. 
 
Table 9.3-12: Prevalence of HPV-16 and HPV-18 by cytology in Austria, Western Europe and the world [28] 
 
 
 
some data also in WHO 
report 
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Figure 9.3-3: Ten most frequent HPV-types among women with and without cervical lesions in Austria 
compared to Western Europe and the World [28] 
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9.4 Data on the interventions compared  
9.4.1 Screening 
Data on screening can be categorised into data on general Austrian screening 
characteristics, data on state of the art of providing the screening (recom-
mended intervals, age groups, quality assurance methods, organisational is-
sues) and data on test accuracy. 
Characteristics of Screening in Austria 
Information on characteristics of screening (e.g. participation rates) are 
available from routine data which are beyond the scope of the report. Addi-
tionally, published data on the Austrian characteristics are available in the 
WHO report on HPV [28]. These include main characteristics (screening 
ages, intervals etc.) (see table 10.4-1), general coverage  (table 10.4-2), and 
coverage by age (figure 10.4-1). Furthermore, the report presents coverage 
by Austrian regions.  
Table 9.4-1: Main characteristics of cervical cancer screening in Austria [28] 
 
Table 9.4-2: Estimated coverage of cervical cancer screening in Austria [28] 
 
 
 
screening data: Austrian 
characteristics, state of 
the art, test accuracy 
characteristics of 
screening in Austria 
from routine data and 
WHO report 
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Figure 9.4-1: Estimated coverage of cervical cancer screening in Austria, by age and study [28] 
State of the art in screening provision pareninterval, quality 
assuranceparen 
Guidelines have been identified as the primary data source for state of the 
art information on screening programmes. For the state of the art in cervical 
cancer screening an evidence based supranational guideline by the European 
Union has been identified as most relevant [18].  
Generally, no overall standard exists in terms of screening intervals and 
starting/ending age, while there is a clear recommendation in favour of an 
organised screening in contrast to an opportunistic screening. The docu-
ments provide various tables that demonstrate the % reduction in cumula-
tive incidence of cancer depending on different screening intervals, age 
groups screened and coverage rates (see table 10.4-3 for an example) 
 
 
EU guideline for 
information on state of 
the art in screening 
state of the art is 
variable, document 
shows impact from 
different strategies 
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Table 9.4-3: Reduction in cumulative incidence of squamous cell carcinoma of the 
cervix uteri with different screening intervals and coverage rates 
(aged 35-64) in comparison to expectations without screening [18] 
Screening interval Proportion of 
screened 
% Reduction in 
cumulative inci-
dence 
Number of tests 
per woman 
1 year 20% 19 6 
2 year 30% 28 4.5 
3 years 40% 37 4 
5 years 50% 42 3 
10 years 80% 51 2.4 
 
Additionally, some information on recommendations for Austria can be 
found in the document on ‘Vorsorge Neu’ [32]. 
Test accuracy of the Papanicolaou Test parenPap-testparen 
According to the recommendations in chapters 5 and 7, the primary sources 
for test-accuracy data are RCTs and meta-analyses. A recent HTA report on 
HPV-DNA testing in cervical carcinoma screening [33] provides an overview-
table on the sensitivity and specificity of Pap-smears related to CIN 1 to CIN 
3 and invasive carcinoma derived from a number of meta-analyses (see table  
10.4-4). 
 
Table 9.4-4: Sensitivity and specificity of HPV-DNA and Pap-Screening for CIN 1, 
CIN 2, CIN 3 and invasive carcinoma [33] 
 
Furthermore, the report contains a table derived from another secondary 
source on the likelihoods for the Pap-test of obtaining a specific test result 
dependent on different health states.  
 
 
 
data on test accuracy 
from recent HTA report 
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Table 9.4-5: Likelihood to obtain a specific test result dependent on different health 
states [33] 
 
Test accuracy of follow-up diagnostic tests 
The HTA on HPV-DNA testing additionally presents results from a meta-
analysis on the sensitivity and specificity of colposcopy, being 96% and 48% 
respectively [33].   
9.4.2 HPV vaccination 
Efficacy 
According to the standards in the manuals (chapter 5 and 7), vaccine efficacy 
data need to be based on high-level evidence, namely RCTs or meta-analyses. 
Starting already in 1998, a number of RCTs have been undertaken for both, 
the bivalent and quadrivalent vaccine. Publications are available for different 
study endpoints (e.g. immunogenicity, persistent genotype-specific HPV in-
fection, HPV-genotype specific precancerous lesions) and target populations 
(e.g. 15-24 year old females, 18-45 year old females, 16-26 year old males). 
So far, younger age groups from 9 to 14 years that are the primary target 
group for the vaccine have not been included in RCTs that analysed the rele-
vant endpoints (such as precancerous lesions or HPV infection). 
RCTs on the efficacy and safety of the vaccines against cervical HPV infection 
and diseases among females have been published by Koutsky et al. [34], Mao 
et al. [35], Harper et al. [36, 37], Villa et al. [38, 39], by the ’FUTURE I Study 
Group’ and the ‘FUTURE II study group’ on the quadrivalent vaccine (Gar-
land et al. [40], Brown et al. [41], Wheeler et al. [42], Future II Study group 
[43]), by the ‘PATRICIA-trial group’ on the bivalent vaccine (Paavonen et al. 
[44, 45]),  by Munoz et al. [46], by De Carvalho et al. [47] and by Castellsague 
et al. [48]. 
The data that are typically provided in the studies include vaccine efficacy 
against 6/12-months persistent infection and against cervical intraepithelial 
neoplasia (CIN) grade 1, 2 or more (CIN 2+, CIN 3+) that are associated with 
HPV types 16 and 18. The studies usually distinguish between sero- or DNA-
negative females and those that had already been infected. Additionally, in-
HTA report provides 
data on test accuracy of 
colposcopy 
many RCTs  on vaccine 
efficacy available since 
1998 
typical information in 
RCTs: persistent 
infection, CIN 
several types of analysis  
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tention-to-treat and/or per-protocol-analysis study results are presented 
(see table 10.4-6for data example). Usually, data on the cumulative incidence 
of certain outcome parameters are included in the papers. Finally, safety 
outcomes are presented.  
Table 9.4-6: End-of-study efficacy against the combined incidence of vaccine type-
related infection of 6 months duration, CIN or EGL [48] 
 
Recently, an RCT on the efficacy of the quadrivalent vaccine in males has 
been published [49]. Among other information, the study presents results on 
persistent infection and on DNA detection for HPV types 6, 11, 16 and 18 
(see table 10.4-7). 
 
 
recently RCT on vaccine 
efficacy in males 
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Table 9.4-7: Efficacy against persistent infection with HPV types 6, 11, 16, or 18 and against detection of HPV DNA in the intention-to-treat-population* [49] 
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Specific subgroup analyses from quadrivalent vaccine trial data have been 
conducted on the efficacy against cervical disease in subjects with prior HPV 
infection [50] and on the impact of the vaccine on all HPV-associated genital 
disease in women [51]. In the former case, the information in the study may 
be relevant for model information that is related to natural protection after 
HPV infection. The latter provides information on the impact of the vaccina-
tion on diseases irrespective of the HPV-type (see table 10.4-8 for the type of 
information provided). However, both studies retrospectively analysed data 
from trials that have not originally been designed to analyse the issues in 
question.  
 
Table 9.4-8: Reductions in any cervical intraepithelial neoplasia (CIN) and any 
external genital lesion irrespective of causal human papillomavirus (HVP) type* 
[51] 
  
In the meantime, the results from the single trials have been summarised in 
systematic reviews or meta-analyses. These include a meta-analysis of the 
efficacy and safety of prophylactic vaccines (bivalent and quadrivalent) 
against cervical HPV infection and diseases among women [52], a systematic 
review on long-term protection against cervical infection [53] and a review 
of the bivalent vaccine-impact on premalignet cervical lesions [54].  
Subgroup analysis also 
available: subjects with 
prior infection, impact 
on all HPV-associated 
genital diseases 
systematic reviews and 
meta-analysis also 
available 
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The meta-analysis [52] provides pooled data for the vaccine efficacy on per-
sistent infection and on precancerous lesions by HPV type (16, or 18) and by 
type of precancerous lesion (CIN1+, CIN2+). Furthermore, pooled data on 
cross-protection against HPV 31/33/45/52/58 in terms of infection and 
precancerous lesions are presented. The systematic review [53] may be 
relevant for additional information on the comparative antibody levels in 
various age-groups of the bivalent and quadrivalent vaccine. The review of 
bivalent vaccine studies [54] summarises evidence from phase II and phase 
III studies. Its additional value may be that long-term data of up to 8.4 years 
concerning the efficacy of the bivalent vaccine on persistent HPV infection 
are presented. 
Safety 
Data on the vaccines’ safety are provided in various different types of stud-
ies: They can be obtained from the single RCTs cited earlier, from pooled 
analyses of RCTs (e.g. analysis on the risk of miscarriage by Wacholder et al. 
[55]),  from the meta-analysis on RCTs [52], from reports by public health 
institutes (e.g. Centre for disease control and prevention  [56], Paul-Ehrlich 
Institut [57]) or from separate adverse event reporting studies (e.g. Van Ko-
oster et al. [58] for the Netherlands) and from analyses of adverse events re-
porting systems (e.g. Slade et al. [59]). Due to the different study designs the 
data provided differ in their characteristics (see table 10.4-9 for an example 
ondata from an analysis of an adverse events reporting system). 
Table 9.4-9: Most common and other selected quadrivalent HPV adverse events 
following immunisation in the United States, reported to VAERS June 
1, 2006, through December 31, 2008 [59] 
 
variety of study types 
on safety 
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Duration of protection 
The longest follow-up data are available for a monovalent vaccine (against 
HPV-16) that has been developed prior to the licensed bivalent and 
quadrivalent vaccines. The study observed immunogenicity for 8 years [60]. 
De Carvalho et al. [47]  report efficacy and immunogenicity of the bivalent 
vaccine up to 7.3 years. In their tables the authors present the total number 
of women in the intervention and placebo group and the number of women 
reporting ≥1 event. Immunogenicity is described in figures only without de-
tailed numerical data. 
HPV-vaccination schedule and coverage 
The WHO report on HPV provides information on the licensure status of the 
bivalent and quadrivalent HPV-vaccine.  
Information on the country recommendations concerning primary target 
groups, catch-up groups and the vaccination of males as well as on the deliv-
ery strategy can be obtained from the document published by the advisory 
board for the ministry of health (Oberster Sanitatsrat) [61].  
Since the HPV-vaccination has not been publicly funded so far, figures on the 
current proportion of coverage are not available for Austria. Consequently, 
figures on the proportion of coverage for a publicly funded HPV-vaccination 
programme need always be based on assumptions. Published data source to 
obtain estimates for these assumptions are published proportions in other 
publicly funded vaccination programmes. Such figures have been published 
in the WHO report on HPV [28] Figure 10.4-2 and figure 10.4-3 demonstrate 
examples for diphteria, tetanus and pertussis and for measles.  
 
longest study 8 years 
information on 
vaccination schedule 
from WHO and Austrian 
sources 
WHO document 
provides coverage rates 
for other vaccines 
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Figure 9.4-2: Diphteria, Tetanus and Pertussis coverage (3rd dose completed) in 
Austria [28] 
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Figure 9.4-3: Measles-containing vaccine coverage in Austria [28] 
 
9.5 Data on sexual activity 
The WHO report from 2010 states that no Austrian data are available on 
sexual behaviour (e.g. onset of sexual intercourse, high-risk sexual behav-
iour). Some data are provided on reproductive health behaviour in Austria 
(e.g. on the use of contraception, age of marriage) that are themselves ex-
tracted from published secondary sources such as reports from the World 
Bank or the United Nations [28].  
9.6 Data on resource utilisation 
According to the ‚2007 report on HPV vaccination modelling’ [16] the follow-
ing resource categories need to be taken into account for calculating the di-
rect costs 
b Routine screening using pap smear 
b Diagnostic follow-up in women with positive pap smears 
b Management/treatment of precancerous lesions (especially CIN 3) 
no Austrian data 
available on sexual 
activity 
6 resource categories 
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b Diagnostic procedures for invasive cervical carcinomas 
b Treatment of invasive cervical carcinomas 
b Vaccination 
As summarised in chapter 7, appropriate data sources for resource use pat-
terns are routine data, clinical practice guidelines and expert opinions. For 
the purpose of this report, clinical practice guidelines are the only published 
secondary data source that is relevant. 
Currently, there exists one published guideline on the diagnostic and treat-
ment of precancerous lesions [62] and one on the treatment of invasive cer-
vical carcinoma [63].  
From both guidelines, information on the types of diagnostic procedures 
used and on the treatment methods applied can be obtained. Hence, they are 
helpful for identifying relevant resource categories and technologies that 
need to be taken into account in the model and for which information on unit 
costs need to be collected. 
The guidelines do not provide information on the number of women that are 
diagnosed with precancerous lesions or on the number of women with inva-
sive carcinoma nor do they provide information on which proportion of 
women receives which type of treatment in the case of alternative options. 
Finally, no information can be obtained from the two guidelines on the po-
tential discrepancies between the recommendations in the guidelines and 
the real world practice patterns.  
9.7 Data on unit costs 
According to the information from the chapter 7, data on unit costs need to 
be country-specific and, thus, they will hardly be found in published litera-
ture.  
In the case of HPV-vaccination no appropriate published document that pro-
vides information on relevant unit costs for HPV-vaccination modelling has 
existed prior to the HTA-report from 2007. Hence, the primary data sources 
for Austrian-specific unit costs will be databases on tariffs (Honorarord-
nungsdatenbank) and routine data (e. g. to obtain information on hospital 
charges). As it has been stated in the method section, these data sources will 
not be described in this report.  
In the case of HPV-vaccination modelling, both, a report [16] and a paper 
[64] have been published that provide detailed information on unit costs in 
the appendix of the report and in  table 2 of the paper. 
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10 Discussion 
In chapter 10, the guidance on possible relevant data sources that has been 
summarised in the first part of this report has been applied to the case of 
‘HPV vaccination modelling’.  
Generally, the guidance was of help in identifying the starting point for the 
data search and in getting an idea on what type of data sources may be used 
for what type of model parameters. In particular, the summary showed for 
what model parameters secondary published literature may be the preferred 
first choice (e.g. for parameters dealing with efficacy) and for which types of 
parameters other secondary data will likely be appropriate (e.g. for parame-
ters on costs).  
Yet, because none of the manuals provided detailed information on the 
strengths and weaknesses of those data, the guidance may not be of enough 
support for persons that are little acquainted with the subjects involved such 
as clinical epidemiology.  
Moreover, some limitations appeared when it came to the specific applica-
tion in a modelling exercise. For example for data on the natural history of 
the disease, manuals recommend observational studies/disease registries. 
Due to the nature of the disease and the available treatment options such 
studies are hardly available in the case of cervical cancer and the few studies 
that exist are more than 20 years old and may not be transferable to the cur-
rent female population. Hence, the recommendations in the manuals will not 
be applicable to every single case. 
Furthermore, some data that are presented in the published documents are 
conflicting. For example the data on cervical carcinoma incidence and mor-
tality from the WHO document [28] in chapter 10.3.2 are different from 
those presented by the ‘Statistik Austria’ [65] where mortality and incidence 
rates are lower than in the WHO document. The manuals provide only lim-
ited information on how to deal with conflicting data although the issue was 
briefly mentioned in context with expert opinions that may be useful in such 
situations. 
Although a number of data have been identified in published papers and re-
ports, these data my not be detailed enough for parameterising the ‘HPV 
vaccination’ model. For example, one document on cervical cancer [20] 
states that the time period between infection and precancerous lesions is 
approximately 10 years without further details on risk differences that may 
depend on the HPV genotype. One may therefore at least need to check the 
references cited in this document for further information or more detailed 
data. Another example are the data from clinical studies. They are usually 
presented in an aggregated way while information would often be needed on 
specific subgroups or patient characteristics (e.g. smoking status, age).  
Additionally, before using data that have been presented in chapter 10 in the 
modelling exercise, the context where they have been extracted from needs 
to be taken into account carefully. For example, modellers need to check 
thoroughly on what type of analysis vaccine-efficacy data are based on (e.g. 
per protocol analysis, intention-to-treat analysis).  
For a number of issues (such as the process of HPV transmission), data are 
generally missing. For other data categories, specific Austrian data are miss-
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ing (such as prevalence or incidence of precancerous lesions) and, finally, in 
many cases data may not be in the format that is needed for the model.  
Hence, published literature can only provide one piece of a jigsaw in addition 
to further sources of information. Additionally, the methods from chapter 8 
on how to further process the data may be useful, however they need to be 
applied in cooperation with the relevant experts to guarantee high modelling 
standards.  
Finally, the limitations of this report need to be taken into account when us-
ing the information for the ongoing modelling exercise. Firstly, the literature 
cited is not based on a systematic literature search for every single informa-
tion category. Secondly, the studies have not been subject to a quality check. 
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11 Conclusion 
This report summarises the current modelling guidelines that are used 
within the context of HTA in terms of how to identify data for parameterising 
models, in terms of possible relevant types of data and in terms of further 
data processing methods. 
While the report is not to be regarded as exhaustive, it is intended to provide 
a starting point for developers of models to ensure a structured and meth-
odological sound approach to building decision-analytical models for HTA.  
Since the correct handling of the different types of data requires many dif-
ferent experts from various disciplines, this report cannot replace a continu-
ous process of knowledge exchange between experts from HTA, epidemiolo-
gists and modelling specialists in Austria during a modelling project.  
One part of such a dialogue may be the cooperation between the information 
specialist in an HTA unit and the model developer. Another part of coopera-
tion may be between the model-developer and statisticians that are familiar 
with clinical epidemiology.  
Hence, the data that are provided for the HPV-vaccination model exercise in 
chapter 10 need now to be handled further by the model developers in an it-
erative process with the other partners involved. 
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